Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)
Take L DMSO stock solution
Extended protocols may be appropriate for individuals with significant body composition goals, those who respond gradually to therapy, or patients seeking comprehensive metabolic optimization under close medical supervision
In some embodiments, the formulations or compositions described herein have a pH between about 5 and about 8, or between about 6 and about 7, or between about 6.5 and about 7, or between about 5.5 and about 7.5, or between about 7.1 and about 7.7, and have a concentration of active pharmaceutical ingredient between about 1 and about 100 mM
Still, animal products may also contain other substances that can interfere with vitamin B12 absorption, so vegetarians and vegans may be at risk of deficiency
JCO Oncology Practice